[Form 4] Edwards Lifesciences Corp Insider Trading Activity

Rhea-AI Filing Summary

Edwards Lifesciences (EW) – Form 4 insider transaction

Company Vice President, JAPAC, Daniel J. Lippis reported the sale of 4,114 EW common shares on 07/28/2025. Trades were executed in multiple lots at prices between $79.45 and $79.47, producing a weighted-average sale price of $79.4605. Following the sale, Lippis’ direct beneficial ownership stands at 22,001.9103 shares. No derivative transactions were reported and no other changes in ownership were disclosed.

The filing is limited to this single transaction; it does not detail additional holdings or option grants. Form 4 timing complies with SEC rules, indicating the trade likely settled on, or shortly before, the reported date.

Positive

• Timely compliance with SEC Section 16(a) reporting requirements, indicating strong governance processes.
• Officer retains 22,001.9103 shares, preserving equity alignment with shareholders.

Negative

• Sale of 4,114 shares (~15% of the officer's prior direct holdings) marginally reduces insider ownership and may be viewed as a slight negative signal.

Insights

Financial Analyst

TL;DR: Small insider sale; negligible impact on EW valuation.

The transaction represents roughly $0.33 million in proceeds and leaves the officer with about 22 k shares (≈$1.75 million at the sale price). Given EW’s >$45 billion market cap, the sale is immaterial to the share float and earnings outlook. Insider sales can signal caution, but the amount (≈0.004% of shares outstanding) and continuing ownership suggest routine diversification rather than a strategic statement. No derivative exercises or option expirations accompany the sale, further indicating a standard open-market disposition.

Corporate Governance Specialist

TL;DR: Routine Form 4, governance compliance intact.

Timely filing within the two-business-day window demonstrates adherence to Section 16(a). The absence of complex instruments or indirect holdings lowers governance risk. While any insider sale can draw scrutiny, the officer retains a meaningful equity stake, maintaining alignment with shareholder interests. No red flags such as clustered executive sales, large percentage disposals, or Form 144 intentions are evident.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, JAPAC

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2025		S		4,114	D	$79.4605(1)	22,001.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $79.4500 to $79.4701. The price reported above reflects the weighted average sale price. The reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Edwards Lifesciences (EW) shares did Daniel J. Lippis sell?

He sold 4,114 common shares on 07/28/2025.

What price did the EW shares sell for?

Trades ranged from $79.45 to $79.47; the weighted average was $79.4605.

How many EW shares does the insider still own after the sale?

Lippis now directly owns 22,001.9103 shares.

Were any derivative securities involved in this Form 4?

No. No options or other derivatives were reported in Table II.

Does this filing suggest a change in Edwards Lifesciences’ outlook?

The single, modest sale is immaterial to company fundamentals and offers limited insight into EW’s operational outlook.